Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1H5UL | ISIN: LU0569974404 | Ticker-Symbol: 7AA
Tradegate
15.01.25
10:49 Uhr
25,620 Euro
+0,280
+1,10 %
1-Jahres-Chart
APERAM SA Chart 1 Jahr
5-Tage-Chart
APERAM SA 5-Tage-Chart
RealtimeGeldBriefZeit
25,66025,70011:52
25,66025,70011:52
Dow Jones News
382 Leser
Artikel bewerten:
(2)

Aperam S.A.: Aperam update on Q4 2024 market & financial trends

Finanznachrichten News

DJ Aperam update on Q4 2024 market & financial trends

Aperam S.A. / Key word(s): Miscellaneous 
Aperam update on Q4 2024 market & financial trends 
07-Jan-2025 / 06:59 CET/CEST 
=---------------------------------------------------------------------------------------------------------------------- 
 
Aperam update on Q4 2024 market & financial trends 
 
Luxembourg, January 7, 2025 (07:00 CET) - In preparation of the upcoming quarterly results release scheduled for 
Friday, 7 February 2025, we would like to remind market participants of the standing guidance, earnings drivers and 
events that should be considered. 
The Q4 outlook, as specified in the Q3 presentation, the management podcast and during the conference call was: 
   -- Q4 group adjusted. EBITDA higher than in Q3-24 (EUR99m). The seasonal headwind in the summer quarter 
  should turn into tailwind in Q4 which is seasonally stronger in Europe. Normally the Brazil seasonality works 
  against this but it should be a rather mild one this year. In sum, Aperam expects higher steel shipments in Q4 
  compared to Q3. 
   -- Scale effect together with a positive product mix and some positive valuation gains should balance lower 
  realized prices. 
   -- This compares to the Aperam compiled Q4 adjusted EBITDA consensus at EUR109m (average) currently. The 
  consensus is updated & published at: 
  https://www.aperam.com/investors/news-contacts/results 
 
Recycling &   Normalized annual EBITDA of EUR80-85m for the Recycling & Renewables segment. After reaching EUR54m in 
Renewables   9M-24 we expect Q4 to at least plug the year-to-date gap. 
Stainless &   For Q4 we expect higher volumes and a better mix to be balanced by pricing pressure and some valuation 
Electrical   headwind for a comparable result. 
Europe 
Stainless & 
Electrical   Q4 adjusted EBITDA is expected at a comparable level qoq due to a mild seasonal downturn only 
Brazil 
Alloys &    Higher adjusted EBITDA qoq is following the seasonal trough in Q3 . Demand in key markets remains high 
Specialties   and the seasonal uptick in Q4 should close the gap to the EUR80m guidance (9M: EUR56m). 
Services &   Intensifying pricing pressure limits the recovery potential into Q4 for this spot market driven segment 
Solutions    especially as inventory valuation should remain a drag in the earnings bridge. 
Others &    Elimination should turn slightly positive due to inventory reduction. The high level of integration 
Eliminations  between different Aperam businesses like recycling, charcoal, stainless mills and distribution allows 
        to manage inventory just-in-time between segments which is then reflected in eliminations. 
        NWC: Lower net working capital in Q4 will result in a higher free cash flow 
Cash Flow & 
Net Fin. Debt  Capex: EUR150m for 2024 of which 83% has already been spent in 9M 
        Net debt reduction to a level of about 550 million euros is expected at year end of 2024 

Please note that forward guidance for adjusted EBITDA, cash flow and net debt is always provided on a stable commodity price assumption.

Commodity prices & FX 
                   SEP 24 OCT 24 NOV 24 DEC 24 
Nickel LME           USD/t 16,136 16,821 15,720 15,434 
Ferrochrome           USD/t 3,153 3,153 3,042 2,954 
Stainless Scrap         USD/t 1,309 1,265 1,265 1,181 
Stainless CR 2mm 304      USD/t 3,047 2,950 2,843 2,720 
USD/EUR             x   1.11  1.09  1.06  1.05 
USD/BRL 
Source: Bloomberg, Fastmarkets x   5.54  5.62  5.81  6.10 
 
Other items 
Volume seasonality In a normal market, Q4 in Europe is seasonally stronger than Q3 which forms the seasonal trough. In 
          Brazil Q3 forms the seasonal peak followed by a seasonally softer Q4. 
Leadership Journey On track to realise the target gains of EUR75m in 2024. 
Phase 5 
Commodity prices & Market prices might weigh on units with a high spot market exposure like eg Services & Solutions. 
valuation effect  For the group we continue to expect a net positive valuation effect which supports the adjusted 
          EBITDA indication given for Q4. 
Distributor    The inventory cycle was largely neutral. In absolute tonnage inventory remained below the average of 
Inventory:     the past 5 years. 
Current trading & Volumes in Europe remain at a depressed level and pricing pressure has intensified in December. This 
outlook      will be a factor to consider for Q1, together with the peak seasonal trough in Brazil and a 
          valuation headwind versus Q4. 
Universal     The process to acquire Universal Stainless is running according to expectations. The special AGM has 
Stainless     been scheduled on 15 January 2025 where the shareholders of Universal Stainless are asked to vote on 
          the proposed merger. 

Forward Looking Statements

This document may contain forward-looking information and statements about Aperam SA and its subsidiaries. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance. Forward-looking statements may be identified by the words "believe", "expect", "anticipate", "target" or similar expressions. Although Aperam's management believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Aperam's securities are cautioned that forward-looking information and statements are subject to numerous risks and uncertainties, many of which are difficult to predict and generally beyond the control of Aperam, that could cause actual results and developments to differ materially and adversely from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in Aperam's filings with the Luxembourg Stock Market Authority for the Financial Markets (Commission de Surveillance du Secteur Financier). The information is valid only at the time of release and Aperam does not assume any obligation to update or revise its forward-looking statements on the basis of new information, future events, subject to applicable regulation.

Contact

Investor Relations / Thorsten Zimmermann: IR@aperam.com Communication / Ana Escobedo Conover: Ana.Escobedo@aperam.com

-----------------------------------------------------------------------------------------------------------------------

Dissemination of a Financial Wire News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

2062275 07-Jan-2025 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2062275&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face

(END) Dow Jones Newswires

January 07, 2025 00:59 ET (05:59 GMT)

© 2025 Dow Jones News
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.